Prognostic significance of estrogen and progesterone receptor expression in LNG-IUS (Mirena®) treatment of endometrial hyperplasia: An immunohistochemical study

Acta Obstetricia et Gynecologica Scandinavica

Volumn 89, Issue 3, 2010, Pages 393-398

  Akesson, Emelie ^a   Gallos, Ioannis D ^a   Ganesan, Raji ^a   Varma, Rajesh ^b   Gupta, Janesh K ^a  

^a BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Endometrial hyperplasia; Estrogen receptors; LNG IUS; Progesterone receptors; Prognosis

Indexed keywords

AROMATASE; ESTROGEN RECEPTOR ALPHA; LEVONORGESTREL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM HYPERPLASIA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; ENDOMETRIAL HYPERPLASIA; FEMALE; HUMANS; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LEVONORGESTREL; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; STATISTICS, NONPARAMETRIC;

EID: 77749258716     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.3109/00016340903556006     Document Type: Article

References (12)

1. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer. 1985;56: 403-12.
2. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006;106: 812-19.
3. Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia - a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol. 2008;139:169-75.
4. Ehrlich CE, Young PC, Cleary RE. Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications. Am J Obstet Gynecol. 1981;141:539-46.
5. Watanabe K, Sasano H, Harada N, Ozaki M, Niikura H, Sato S, et al. Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies. Am J Pathol. 1995;146: 491-500.
6. Baak JP, Van DB, Steinbakk A, Janssen E, Skaland I, Mutter GL, et al. Lack of PTEN expression in endometrial intraepithelial neoplasia is correlated with cancer progression. Hum Pathol. 2005;36:555-61.
7. International Society of Gynecological Pathologists (ISGP) and WHO. Classification of endometrial hyperplasia; Ronnett BM, Kurman RJ. Precursor lesions of endometrial carcinoma. In: Kurman RJ (ed). Blaustein's pathology of the female genital tract. 5th edn. New York: Springer-Verlag, 2002. pp. 467-500.
8. Huang A, Pettigrew NM, Watson PH. Immunohistochemical assay for oestrogen receptors in paraffin wax sections of breast carcinoma using a new monoclonal antibody. J Pathol. 1996;180:223-27.
9. Kistner RW. Histological effects of progestins on hyperplasia and carcinoma in situ of the endometrium. Cancer. 1959; 12:1106-22.
10. Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol. 1989;160:126-31.
11. Masuzawa H, Badokhon NH, Nakayama K, Konishi I, Nikaido T, Fujii S. Failure of down-regulation of estrogen receptors and progesterone receptors after medroxyprogesterone acetate administration for endometrial hyperplasias. Cancer. 1994;74:2321-28.
12. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol (Oxf). 1982;17:529-36.